Uppsala, Sweden - March 16, 2017 – Orexo’s Annual Report for the 2016 fiscal year has been published and can be downloaded from the company’s website, www.orexo.com. Besides summarizing the business and financial highlights for 2016 the report also provides a deeper insight into Orexo’s strategic agenda, including the development pipeline.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Manager
Tel: +46 18 780 88 00
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.
This information is information that Orexo AB (publ.) is obliged to make public in accordance with the Securities Market Act. The information was submitted for publication at 8.45am CET on
March 16, 2017.
The following files are available for download: